Диссертация (1141189), страница 22
Текст из файла (страница 22)
– P. 1298 - 1310.19.!Bonaca, M.P. Long-term use of ticagrelor in patients with prior myocardialinfarction / M.P. Bonaca, D.L. Bhatt, M. Cohen et al. // England Journal of Medicine.– 2015. –Vol. 372. – P. 1791 - 1800.20.!Mehran, R. Impact of bleeding on mortality after percutaneous coronaryintervention results from a patient-level pooled analysis of the REPLACE-2(randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY(acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI(harmonizing outcomes with revascularization and stents in acute myocardialinfarction) trials / R.
Mehran , S. Pocock , E. Nikolsky et al. // Journal of the AmericanCollege of Cardiology. – 2011. – Vol. 4. – P. 654 - 664.21.!Moscucci, M. Predictors of major bleeding in acute coronary syndromes: theGlobal Registry of Acute Coronary Events (GRACE) / M. Moscucci, K.A. Fox, C.P.Cannon et al. // European Heart Journal. – 2003. – Vol. 24. – P. 1815 – 1823.143!22.!Панченко, Е.П. Тромбозы в кардиологии. Механизмы развития ивозможности терапии / Е.П. Панченко, А.Б Добровольский – М.: ИздательствоСпорт и культура, 1999. – 462 с.23.!Baigent, C.
Collaborative meta–analysis of randomized trials of antiplatelettherapy for prevention of death, myocardial infarction, and stroke in high risk patients /C. Baigent, L. Blackwell, R. Collins et al. // British Medical Journal. – 2002. – Vol.324. – P. 71 – 86.24.!Ruggeri, Z.M. Mechanisms initiating platelet thrombus formation / Z.M.Ruggeri // Journal of Thrombosis and Haemostasis – 1997. – Vol. 78. – P. 611 - 616.25.!Stone, G.W. A prospective natural-history study of coronary atherosclerosis /G.W. Stone, A.
Maehara, A.J. Lansky et al. // New England Journal of Medicine. –2011. – Vol. 364. – P. 226 - 235.26.!Serebruany, V.L. Assessment of bleeding events in clinical trials—proposal ofa new classification / V.L. Serebruany, D. Atar // American Journal of Cardiology. 2007. – Vol. 99. – P. 288 – 290.27.!Hamon, M. Incidence, source, determinants, and prognostic impact of majorbleeding in outpatients with stable coronary artery disease / M. Hamon , G. Lemesle ,O. Tricot et al. // Journal of the American College of Cardiology.
– 2014. – Vol. 64. –P. 1430 - 1436.28.!Steinhubl, S.R. Early and sustained dual oral antiplatelet therapy followingpercutaneous coronary intervention: a randomized controlled trial / S.R. Steinhubl,P.B. Berger, J.T. Mann et al. // JAMA. – 2002. – Vol. 288. – P. 2411 - 2420.29.!An International Randomized Trial Comparing Four Thrombolytic Strategiesfor Acute Myocardial Infarction / The GUSTO Investigators // New England Journal ofMedicine. – 1993. – Vol. 329.
– P. 673 - 682.30.!Chesebro, J.H. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: Acomparison between intravenous tissue plasminogen activator and intravenousstreptokinase. Clinical findings through hospital discharge / J.H. Chesebro, G.Knatterud, R. Roberts et al. // Circulation. – 1987. – Vol. 76. – P. 142 – 154.144!31.!Montalescot, G.
Enoxaparin versus unfractionated heparin in electivepercutaneous coronary intervention / G. Montalescot, H.D. White, R. Gallo et al // NewEngland Journal of Medicine. – 2006. – Vol. 355. – P. 1006 - 1017.32.!Quinn, M. Long-term mortality benefit of abciximab in percutaneousintervention / M. Quinn, A.M. Lincoff, D. Kereiakes et al. // Circulation.
– 2001. –Vol. 37. – P. 2059 - 2065.33.!Stone, G.W. Bivalirudin for patients with acute coronary syndromes / G.W.Stone, B.T. McLaurin, D.A. Cox et al. // New England Journal of Medicine. – 2006. –Vol. 355. – P. 2203 - 2216.34.!Rao, S.V. An updated bleeding model to predict the risk of post-procedurebleeding among patients undergoing percutaneous coronary intervention: a report usingan expanded bleeding definition from the National Cardiovascular Data RegistryCathPCI Registry / S.V.
Rao, L.A. McCoy, J.A. Spertus et al. // Journal of theAmerican College of Cardiology. Cardiovasc. Interv. – 2013. – Vol. 6, № 9. – P. 897 904.35.!Kinnaird, T.D. Incidence, predictors, and prognostic implications of bleedingand blood transfusion following percutaneous coronary interventions / T.D.
Kinnaird,E. Stabile, G.S. Mintz et al. // American Journal of Cardiology. – 2003. – Vol. 92. – P.930 - 935.36.!Кобалава, Ж.Д. Клинические рекомендации: «Сердечно-сосудистый риск ихроническая болезнь почек: стратегии кардио-нефропротекции»/ Ж.Д. Кобалава,И.Н. Бобкова, С.В. Виллевальде и комитет экспертов РКО, Научного обществанефрологов России (НОНР), Российской ассоциации эндокринологов (РАЭ),Российского медицинского общества по артериальной гипертонии (РМОАГ),Национального общества по изучению атеросклероза (НОА) и Российскогонаучногомедицинскогообществатерапевтов(РНМОТ)//Российскийкардиологический журнал.
– 2014. – № 8 (112). – C.7 - 37.37.!Kellum, J.A. Kidney Disease: Improving Global Outcomes (KDIGO) ClinicalPractice Guideline for Acute Kidney Injury / J.A. Kellum, P. Aspelin, R.S. Barsoum145!and AKI Work Group // Kidney Interational Supplements. – 2012. – Vol. 2. – P.
1 138.38.!Go, A.S. Chronic Kidney Disease and the Risks of Death, CardiovascularEvents, and Hospitalization / A.S. Go, G.M. Chertow, D. Fan et al. // New EnglandJournal of Medicine. – 2004. – Vol. 351. – P. 1296-1305.39.!Shi, G.P. Cystatin C deficiency in human atherosclerosis and aortic aneurysms/ G.P. Shi, G.K. Sukhova, A. Grubb et al. // Journal of Clinical Investigation. – 1999. –Vol 104. – P. 1191-1197.40.!Kopoлeнкo,Т.А.Цистатины:регуляцияцистеиновыхпротеазинарушения при опухолевых и воспалительных заболевпниях / Т.А.
Kopoлeнкo,Т.Г. Филатова, М.С. Черканова и соавт. // Биомедицинская химия. – 2008. – № 54(2). – C. 210 - 217.41.!Gauthier, S. Protective mechanisms by cystatin C in neurodegenerativediseases / S.Gauthier, G. Kaur, W. Mi et al. // Frontiers in bioscience (Scholar edition).– 2011. – Vol. 3. – P. 541–554.42.!Peralta, C.A. Detection of chronic kidney disease with creatinine, cystatin C,and urine albumin-to-creatinine ratio and association with progression to end-stagerenal disease and mortality / C.A. Peralta, M.G.
Shlipak, S. Judd et al. // JAMA. –2011. – Vol. 305. – P. 1545 - 1552.43.!Carrasco-Sánchez, F.J. Prognostic value of cystatin C on admission in heartfailure with preserved ejection fraction / F.J. Carrasco-Sánchez, L. Galisteo-Almeda, I.Páez-Rubio et al. // J.
Card. Fail. – 2011. – Vol. 17. – P. 31-38.44.!Shlipak, M.G. Cystatin C versus creatinine in determining risk based on kidneyfunction // M.G. Shlipak, K Matsushita, J. Arnlov et al. // New England Journal ofMedicine. – 2013. – Vol. 369. – P. 932 - 943.45.!Komarov, А. Cystatin C as a risk factor of thrombotic and bleeding events afterelective PCI in patients without severely decreased kidney function: the results of 3years follow-up / А. Komarov, O. Shakmatova, E.
Guskova et al. // European HeartJournal. – 2014. – Vol. 35 (Abstract Supplement). – P. 566 - 567146!46.!Keller, T. Cystatin C and cardiovascular mortality in patients with coronaryartery disease and normal or mildly reduced kidney function: results from theAtheroGene study / T. Keller, C.M. Messow, E. Lubos et al. // European Heart Journal.– 2009. – Vol. 30. – P. 314 - 320.47.!Woitas, R.P.
Cystatin C is independently associated with total andcardiovascular mortality in individuals undergoing coronary angiography. TheLudwigshafen Risk and Cardiovascular Health (LURIC) study // R.P. Woitas, M.E.Kleber, A. Meinitzer et al. // Atherosclerosis. – 2013. – Vol. 229.
– P. 541 - 578.48.!Elbarbary, H.S. Serum cystatin C an early indicator of renal function decline intype 2 diabetes / H.S. Elbarbary, N.A. El-Kafrawy, A.A. Shoaib et al. //AmericanJournal of BioScience. – 2014. – Vol. 2. – P. 89 - 94.49.!Wang Q.P. Assessment of glomerular filtration rate by serum cystatin C inpatients undergoing coronary artery bypass grafting / Q.P.
Wang, J.W. Gu, X.H. Zhanet al. // Annals of Clinical Biochemistry. – 2009. – Vol. 46. – P. 495 - 500.50.!Харченко, М.С. Цистатин С и кровотечения в период госпитализациибольных с острыми коронарными синдромами, леченными без примененияинвазивных вмешательств / М.С. Харченко, А.Д. Эрлих, Е.И. Косенков и соавт. //Кардиология. – 2012. – № 5. – C.
13 – 1951.!Latif, F. In-hospital and 1-year outcomes among percutaneous coronaryintervention patients with chronic kidney diseasein the era of drug-eluting stents:a report from the EVENT (Evaluation of Drug Eluting Stents and IschemicEvents)registry / F. Latif, N.S. Kleiman, D.J. Cohen et al. // Journal of the AmericanCollege of Cardiology. Cardiovasc.
Interv. – 2009. – Vol. 2. – P. 37 – 45.52.!Inker, L.A. Estimating Glomerular Filtration Rate from Serum Creatinine andCystatin C / L.A. Inker, C.H. Schmid, H. Tighiouart et al. CKD-EPI Investigators //New England Journal of Medicine. – 2012. – Vol. 367. – P. 20 - 29.53.!Aradi, D. Expert position paper on the role of platelet function testing inpatients undergoing percutaneous coronary intervention.
Working Group onThrombosis of the European Society of Cardiology / D. Aradi, R.F. Storey, A.Komócsi et al. // European Heart Journal. – 2014. – Vol. 35. – P. 209 - 215.147!54.!Комаров, А.Л. Тестирование функции тромбоцитов для оценки тромбозови кровотечений у больных ИБС, получающих антиагреганты / А.Л. Комаров,Е.П. Панченко // Российский кардиологический журнал. – 2015. – № 3(119). – С.25 -34.55.!Ingerman-Wojenski, C.
Evaluation of electrical aggregometry: comparisonwith optical aggregometry, secretion of ATP, and accumulation of radiolabeledplatelets / C. Ingerman-Wojenski, J.B. Smith, M.J. Silver // Journal of Laboratory andClinical Medicine. – 1983. – Vol. 101.
– P. 44 – 52.56.!Peerschke, E.I. The laboratory evaluation of platelet dysfunction / E.I.Peerschke // Clinics in Laboratory Medicine. – 2002. – Vol. 22 – P. 405 - 420.57.!Gurbel, P.A. Clopidogrel for coronary stenting: response variability, drugresistance, and the effect of pretreatment platelet reactivity // P.A. Gurbel, K.P.
Bliden,B.L Hiatt, C.M. O`Connor // Circulation. – 2003. – Vol. 107 – P. 2908 - 2913.58.!Breet, N.J. Comparison of platelet function tests in predicting clinical outcomein patients undergoing coronary stent implantation / N.J. Breet, J.W. van Werkum, H.J.Bouman et al. // JAMA. – 2010. – Vol.303, №8. – P. 754 - 762.59.!Lordkipanidze, M. Comparison of four tests to assess inhibition of plateletfunction by clopidogrel in stable coronary artery disease patients / M.
Lordkipanidze,C. Pharand, T. A. Nguyen et al. // European Heart Journal. – 2008. – Vol. 29, № 23. –P. 2877 – 2885.60.!Brar, S.S. Impact of platelet reactivity on clinical outcomes after percutaneouscoronary intervention. A collaborative meta-analysis of individual participant data /S.S. Brar, J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
